Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia

Current Topics in Medicinal Chemistry

Volumn 7, Issue 11, 2007, Pages 1131-1136

  Foster, Alan C ^a   Chen, Chen ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Agouti related peptide; Anorexia; Body weight regulation; Cachexia; Hypothalamus; MC4 receptor; Melanocortin

Indexed keywords

2 [2 [2 (5 BROMO 2 METHOXYPHENYL)ETHYL] 3 FLUOROPHENYL] 4,5 DIHYDRO 1H IMIDAZOLE; AGOUTI RELATED PROTEIN[83-132]; HORMONE RECEPTOR AFFECTING AGENT; HORMONE RECEPTOR BLOCKING AGENT; MB 243; MBP 10; MCL 0042; MCL 0129; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR ANTAGONIST; MLC 0042; MLC 0129; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NBI 12I; RECEPTOR SUBTYPE; TETRAHYDROISOQUINOLINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; BODY MASS; BODY WEIGHT; CACHEXIA; CANCER; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DRUG SELECTIVITY; FOOD INTAKE; GENE MUTATION; HUMAN; KIDNEY FAILURE; LEAN BODY WEIGHT; LIVER FAILURE; LUNG DISEASE; METABOLISM; NONHUMAN; OBESITY; PATHOGENESIS; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; WASTING SYNDROME;

ANIMALS; CACHEXIA; DRUG DESIGN; HUMANS; PEPTIDES; RECEPTOR, MELANOCORTIN, TYPE 4;

EID: 34447276950     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780906663     Document Type: Review

References (47)

1. Cone, R. D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci., 2005, 8, 571-8.
2. Schwartz, M. W.; Woods, S. C.; Porte, D., Jr.; Seeley, R. J.; Baskin, D. G. Central nervous system control of food intake. Nature, 2000, 404, 661-71.
3. Huszar, D.; Lynch, C. A.; Fairchild-Huntress, V.; Dunmore, J. H.; Fang, Q.; Berkemeier, L. R.; Gu, W.; Kesterson, R. A.; Boston, B. A.; Cone, R. D.; Smith, F. J.; Campfield, L. A.; Burn, P.; Lee, F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell, 1997, 88, 131-41.
4. O'Rahilly, S.; Yeo, G. S.; Farooqi, I. S. Melanocortin receptors weigh in, Nat. Med., 2004, 10, 351-2.
5. Yaswen, L.; Diehl, N.; Brennan, M. B.; Hochgeschwender, U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat. Med., 1999, 5, 1066-70.
6. Lubrano-Berthelier, C.; Cavazos, M.; Dubern, B.; Shapiro, A.; Stunff, C. L.; Zhang, S.; Picart, F.; Govaerts, C.; Froguel, P.; Bougneres, P.; Clement, K.; Vaisse, C. Molecular genetics of human obesity-associated MC4R mutations. Ann. N. Y. Acad. Sci., 2003, 994, 49-57.
7. Fan, W.; Boston, B. A.; Kesterson, R. A.; Hruby, V. J.; Cone, R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 1997, 385, 165-8.
8. Lu, X. Y.; Nicholson, J. R.; Akil, H.; Watson, S. J. Time course of short-term and long-term orexigenic effects of Agouti-related protein (86-132). Neuroreport, 2001, 12, 1281-4.
9. Balthasar, N.; Dalgaard, L. T.; Lee, C. E.; Yu, J.; Funahashi, H.; Williams, T.; Ferreira, M.; Tang, V.; McGovern, R. A.; Kenny, C. D.; Christiansen, L. M.; Edelstein, E.; Choi, B.; Boss, O.; Aschkenasi, C.; Zhang, C. Y.; Mountjoy, K.; Kishi, T.; Elmquist, J. K.; Lowell, B. B. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell, 2005, 123, 493-505.
10. Larkin, M. Thwarting the dwindling progression of cachexia. Lancet, 1999, 351, 1336.
11. Laviano, A.; Meguid, M. M.; Inui, A.; Muscaritoli, M.; Rossi-Fanelli, F. Therapy insight: Cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat. Clin. Pract. Oncol., 2005, 2, 158-65.
12. Tisdale, M. J. Biology of cachexia. J. Natl. Cancer Inst., 1997, 89, 1763-73.
13. Plata-Salaman, C. R. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition, 2000, 16, 1009-12.
14. Scarlett, J. M.; Marks, D. L. The use of melanocortin antagonists in cachexia of chronic disease. Expert Opin. Investig. Drugs, 2005, 14, 1233-9.
15. Raposinho, P. D.; Castillo, E.; d'Alleves, V.; Broqua, P.; Pralong, F. P.; Aubert, M. L. Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes. Endocrinology, 2000, 141, 4419-27.
16. Small, C. J.; Kim, M. S.; Stanley, S. A.; Mitchell, J. R.; Murphy, K.; Morgan, D. G.; Ghatei, M. A.; Bloom, S. R. Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes, 2001, 50, 248-54.
17. Foster, A. C.; Joppa, M.; Markison, S.; Gogas, K. R.; Fleck, B. A,; Murphy, B. J.; Wolff, M.; Cismowski, M. L; Ling, N.; Goodfellow, V. S.; Chen, C.; Saunders, J.; Conlon, P. J. Body weight regulation by selective MC4 receptor agonists and antagonists. Ann. N. Y. Acad. Sci., 2003, 994, 103-10.
18. Marks, D. L.; Ling, N.; Cone, R. D. Role of the central melanocortin system in cachexia. Cancer Res., 2001, 61, 1432-8.
19. Wisse, B. E.; Frayo, R. S.; Schwartz, M. W.; Cummings, D. E. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology, 2001, 142, 3292-301.
20. Huang, Q. H.; Hruby, V. J.; Tatro, J. B. Role of central melanocortins in endotoxin-induced anorexia. Am. J. Physiol., 1999, 276, R864-71.
21. Joppa, M. A.; Ling, N., Chen, C.; Gogas, K. R.; Foster, A. C.; Markison, S. Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia. Peptides, 2005, 26, 2294-301.
22. Cheung, W.; Yu, P. X.; Little, B. M.; Cone, R. D.; Marks, D. L.; Mak, R. H. Role of leptin and melanocortin signaling in uremia-associated cachexia. J. Clin. Invest., 2005, 115, 1659-65.
23. Mak, R. H.; Cheung, W.; Cone, R. D.; Marks, D. L. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int., 2006, 69, 794-7.
24. Butler, A. A.; Kesterson, R. A.; Khong, K.; Cullen, M. J.; Pelleymounter, M. A.; Dekoning, J.; Baetscher, M.; Cone, R. D. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology, 2000, 141, 3518-21.
25. Marks, D. L.; Butler, A. A.; Turner, R.; Brookhart, G.; Cone, R. D. Differentail role of melanocortin receptor subtypes in cachexia. Endocrinology, 2003, 144, 1513-23.
26. Getting, S. J.; Allcock, G. H.; Flower, R.; Ferretti, M. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J. Leukoc. Biol., 2001, 69, 98-104.
27. Cowley, M. A.; Smart; J. L.; Rubinstein, M.; Cerdan, M. G.; Diano, S.; Horvath, T. L.; Cone, R. D.; Low, M. J. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature, 2001, 411, 480-4.
28. Sebhat, I. K.; Martin, W. J.; Ye, Z.; Barakat, K.; Mosley, R. T.; Johnston, D. B.; Bakshi, R.; Palucki, B.; Weinberg, D. H.; MacNeil, T.; Kalyani, R. N.; Tang, R.; Stearns, R. A.; Miller, R. R.; Tamvakopoulos, C.; Strack, A. M.; McGowan, E.; Cashen, D. E.; Drisko, J. E.; Hom, G. J.; Howard, A. D.; Maclntyre, D. E.; van der Ploeg, L. H.; Patchett, A. A.; Nargund, R. P. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(IR)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl4-(1H-1,2,4-triazol-l-ylmethyl)piperidin-1-yl]-2- oxoethylamine (1), a potent selective, melanocortin subtype-4 receptor agonist. J. Med. Chem., 2002, 45, 4589-93.
29. Xi, N.; Hale, C.; Kelly, M. G.; Norman, M. H.; Stec, M.; Xu, S.; Baurngartner, J. W.; Fotsch, C. Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core. Bioorg. Med. Chem. Lett., 2004, 14, 377-81.
30. Chen, C.; Pontillo, L; Fleck, B. A.; Gao, Y.; Wen, J.; Tran, J. A.; Tucci, F. C.; Marinkovic, D.; Foster, A. C.; Saunders, J. 4-((2R)-[3-Aminopropionylamidol ] -3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2- thienyl)ethyl-aminomethyl] phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist-design, synthesis, and characterization. J. Med Chem., 2004, 47, 6821-30.
31. Pontillo, J.; Tran, J. A.; Fleck, B. A.; Marinkovic, D.; Arellano, M.; Tucci, F. C.; Lanier, M.; Nelson, J.; Parker, J.; Saunders, J.; Murphy, B.; Foster, A. C.; Chen, C. Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett., 2004, 14, 5605-9.
32. Pontillo, J.; Tran, J. A.; Markison, S.; Joppa, M.; Fleck, B. A.; Marinkovic, D.; Arellano, M.; Tucci, F. C.; Lanier, M.; Nelson, J.; Saunders, J.; Hoare, S. R.; Foster, A. C.; Chen, C. A potent and selective nonpeptide antagonist of the melanocortin-4 receptor induces food intake in satiated mice. Bioorg. Med. Chem. Lett., 2005, 15, 2541-6.
33. Pontillo, L; Marinkovic, D.; Tran, J. A.; Arellano, M.; Fleck, B. A.; Wen, J.; Tucci, F. C.; Nelson, J.; Saunders, J.; Foster, A. C.; Chen, C. Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett., 2005, 15, 4615-8.
34. Tran, J. A.; Pontillo, J.; Arellano, M.; Fleck, B. A.; Tucci, F. C.; Marinkovic, D.; Chen, C. W.; Saunders, J.; Foster, A. C.; Chen, C. Structure-activity relationship of a series of cyclohexylpiperidines bearing an amide side chain as antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett., 2005, 15, 3434-8.
35. Tucci, F. C.; White, N. S.; Markison, S.; Joppa, M.; Tran, J. A.; Fleck, B. A.; Madan, A.; Dyck, B. P.; Parker, J.; Pontillo, J.; Arellano, L. M.; Marinkovic, D.; Jiang, W.; Chen, C. W.; Gogas, K. R.; Goodfellow, V. S.; Saunders, J.; Foster, A. C.; Chen, C. Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines. Bioorg. Med. Chem. Lett., 2005, 15, 4389-95.
36. Palucki, B. L.; Park, M. K.; Nargund, R. P.; Ye, Z.; Sebhat, I. K.; Pollard, P. G.; Kalyani, R. N.; Tang, R.; Macneil, T.; Weinberg, D. H.; Vongs, A.; Rosenblum, C. I.; Doss, G. A.; Miller, R. R.; Stearns, R. A.; Peng, Q.; Tamvakopoulos, C.; McGowan, E.; Martin, W. J.; Metzger, J. M.; Shepherd, C. A.; Strack, A. M.; Macintyre, D. E.; Van der Ploeg, L. H.; Patchett; A. A. Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4- (1,1-dimethylethyl)-amino] carbonyl]-1-pipe ridinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl- 2-piperazinecarbo xamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett., 2005, 15, 171-5.
37. Arasasingham, P. N.; Fotsch, C.; Ouyang, X.; Norman, M. H.; Kelly, M. G.; Stark, K. L.; Karbon, B.; Hale, C.; Baumgartner, J. W.; Zambrano, M.; Cheetham, J.; Tamayo, N. A. Structure-activity relationship of (1-aryl-2- piperazinylethyl)piperazines: antagonists for the AGRP/ melanocortin receptor binding. J. Med. Chem., 2003, 46, 9-11.
38. Chaki, S.; Oshida, Y.; Ogawa, S.; Funakoshi, T.; Shimazaki, T.; Okubo, T.; Nakazato, A.; Okuyama, S. MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol. Biochem Behav., 2005, 82, 621-6.
39. Vos, T. J.; Caracoti, A.; Che, J. L.; Dai, M.; Farrer, C. A.; Forsyth, N. E.; Drabic, S. V.; Horlick, R. A.; Lamppu, D.; Yowe, D. L.; Balani, S.; Li, P.; Zeng, H.; Joseph, I. B.; Rodriguez, L. E.; Maguire, M. P.; Patane, M. A.; Claiborne, C. F. Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]- 3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J. Med. Chem., 2004, 47, 1602-4.
40. Marsilje, T. H.; Roses, J. B.; Calderwood, E. F.; Stroud, S. G.; Forsyth, N. E.; Blackburn, C.; Yowe, D. L.; Miao, W.; Drabic, S. V.; Bohane, M. D.; Scott Daniels, J.; Li, P.; Wu, L.; Patane, M. A.; Claiborne, C. F. Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R). Bioorg. Med. Chem. Lett., 2004, 14, 3721-5.
41. Vos, T. J.; Balani, S.; Blackburn, C.; Chau, R. W.; Danca, M. D.; Drabic, S. V.; Farrer, C. A.; Patane, M. A.; Stroud, S. G.; Yowe, D. L.; Claiborne, C. F. Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 2302-5.
42. Nicholson, J. R.; Kohler, G.; Schaerer, F.; Senn, C.; Weyermann, R; Hofbauer, K. G. Peripheral Administration of a Melanocartin 4-Receptor Inverse Agonist Prevents Loss of Lean Body Mass in Tumour-Bearing Mice. J. Pharmacol. Exp. Ther., 2006, 317, 771-7.
43. Markison, S.; Foster, A. C.; Chen, C.; Brookhart, G. B.; Hesse, A.; Hoare, S. R.; Fleck, B. A.; Brown, B. T.; Marks, D. L. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a smallmolecule melanocortin-4 receptor antagonist. Endocrinology, 2005, 146, 2766-73.
44. Haskell-Luevano, C.; Monck, E. K. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul. Pept., 2001, 99, 1-7.
45. Nijenhuis, W. A.; Oosterom, J.; Adan, R. A. AgRP(93-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol., 2001, 15, 164-71.
46. Adan, R. A. Edogenous inverse agonists and constitutive receptor activity in the malanocortin system. Trends Pharm. Sci., 2006, 27, 183-6.
47. Srinivasan, S.; Lubrano-Berthelier, C.; Govaerts, C.; Picard, F.; Santiago, P.; Conklin, B. R.; Vaisse, C. Constitutive activity of the mclanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest., 2004, 114, 1158-64.